{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:08:33Z","timestamp":1788052113572,"version":"build-2784847793"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204758"],"award-info":[{"award-number":["82204758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Bevacizumab (BV) is widely used in routine cancer treatment and clinical therapy in combination with many other agents. This study aims to describe and analyse post-market cases of pulmonary haemorrhage and haemoptysis reported with different BV treatment regimens by mining data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Data were collected from the FAERS database between 2004 Q1 and 2023 Q1. Disproportionality analysis including the reporting odds ratio (ROR) was employed to quantify the signals of disproportionate reporting of pulmonary haemorrhage and haemoptysis adverse events (AEs) associated with BV-related treatment regimens. The demographic characteristics, time to onset and outcomes were further clarified.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 55,184 BV-associated reports were extracted from the FAERS database, of which 497 reports related to pulmonary haemorrhage and haemoptysis. Overall, the median onset time of pulmonary haemorrhage and haemoptysis AEs was 43 days (interquartile range (IQR) 15-117 days). In the subgroup analysis, BV plus targeted therapy had the longest median onset time of 90.5 days (IQR 34-178.5 days), while BV plus chemotherapy had the shortest of 40.5 days (IQR 14\u201390.25). BV plus chemotherapy disproportionately reported the highest percentage of death (148 deaths out of 292 cases, 50.68%). Moreover, the BV-related treatments including four subgroups in our study demonstrated the positive signals with the association of disproportionate reporting of pulmonary haemorrhage and haemoptysis. Notably, BV plus chemotherapy showed a significant higher reporting risk in pulmonary haemorrhage and haemoptysis signals of disproportionate reporting in comparison to BV monotherapy (ROR 5.35 [95% CI, 4.78\u20136.02] vs. ROR 4.19 [95% CI, 3.56\u20134.91], <jats:italic>p<\/jats:italic> = 0.0147).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study characterized the reporting of pulmonary haemorrhage and haemoptysis, along with the time to onset and demographic characteristics among different BV-related treatment options. It could provide valuable evidence for further studies and clinical practice of BV.<\/jats:p>","DOI":"10.3389\/fphar.2024.1339505","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:44:50Z","timestamp":1719204290000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Huiping","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/Jco.2012.44.4711","article-title":"Bevacizumab in stage ii-iii colon cancer: 5-year update of the national surgical adjuvant breast and bowel project c-08 trial","volume":"31","author":"Allegra","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e51780","DOI":"10.1371\/journal.pone.0051780","article-title":"The impact of bevacizumab (avastin) on survival in metastatic solid tumors - a meta-analysis and systematic review","volume":"8","author":"Amit","year":"2013","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.21037\/tlcr-21-464","article-title":"Immune-related adverse event profile of combination treatment of pd-(l)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the fda adverse event reporting system","volume":"10","author":"Bai","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous adr reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ml18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (avex): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.lungcan.2011.11.020","article-title":"Mo19390 (sail): bleeding events in a phase iv study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous nsclc","volume":"76","author":"Dansin","year":"2012","journal-title":"Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s12029-012-9368-3","article-title":"A phase ii study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A fox chase extramural research study","volume":"43","author":"Dotan","year":"2012","journal-title":"J. Gastrointest. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (vegf) and vascular endothelial growth factor receptor (vegfr) targeting angiogenesis inhibitors; a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-vegf antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15\u00a0years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1200\/JCO.22.02761","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (folfox4) for previously treated metastatic colorectal cancer: Results from the eastern cooperative oncology group study e3200","volume":"41","author":"Giantonio","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/cas.13096","article-title":"Bevacizumab for non-small-cell lung cancer: a nested case control study of risk factors for hemoptysis","volume":"107","author":"Goto","year":"2016","journal-title":"Cancer Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-022-02713-6","article-title":"Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation","volume":"21","author":"Guo","year":"2023","journal-title":"BMC Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000314980","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010","journal-title":"Oncology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/jjco\/hyv182","article-title":"Bevacizumab safety in Japanese patients with colorectal cancer","volume":"46","author":"Hatake","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40360-020-00447-w","article-title":"Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the fda adverse event reporting system","volume":"21","author":"Huang","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1200\/Jco.22.02543","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41598-020-58994-5","article-title":"Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis","volume":"10","author":"Kanbayashi","year":"2020","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"15619","DOI":"10.1038\/s41598-022-19887-x","article-title":"Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database","volume":"12","author":"Kanbayashi","year":"2022","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jjco\/hyz125","article-title":"Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study","volume":"49","author":"Motoo","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"Egfr-tki-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"Jama Oncol."},{"key":"B26","volume-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi","year":"2012"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/annonc\/mdr463","article-title":"Predicting and managing the risk of pulmonary haemorrhage in patients with nsclc treated with bevacizumab: a consensus report from a panel of experts","volume":"23","author":"Reck","year":"2012","journal-title":"Ann. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/Jco.2007.14.5466","article-title":"Phase iii trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"B30","first-page":"523","article-title":"Bevacizumab (avastin)","volume":"36","author":"Shimoyama","year":"2009","journal-title":"Gan Kagaku Ryoho"},{"key":"B31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage ii to iii triple-negative breast cancer: calgb 40603 (alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1161\/01.Atv.19.7.1757","article-title":"Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo","volume":"19","author":"Weltermann","year":"1999","journal-title":"Arter. Throm Vas"},{"key":"B34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging us food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"ARTN100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and fda pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"Eclinicalmedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1339505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:44:54Z","timestamp":1719204294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1339505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":35,"alternative-id":["10.3389\/fphar.2024.1339505"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1339505","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"article-number":"1339505"}}